Melanocortin type 4 receptor agonist piperidinoylpyrrolidines

A compound of formula (I):

• wherein
• one of X and Y is N and the other is CH,
• R is F, Cl, CN, CF3 or methoxy, with the proviso that when Y is N, R is not F or Cl,
• R1 is phenyl, 2-pyridyl, C3-C6 cycloalkyl or CH2(C3-C6 cycloalkyl), wherein the ring moiety of said phenyl, 2-pyridyl, C3-C6 cycloalkyl or CH2(C3-C6 cycloalkyl) is optionally substituted with one to four substituents independently selected from F, Cl, CN, methyl and methoxy,
• R2 is H, F or Cl, with the proviso that when Y is N, R2 is not F or Cl,
• Het is a 6-membered ring containing one or 2 N atoms, wherein the ring is either aromatic, or contains 2 double bonds in the ring and a 0 substituent, which ring is optionally substituted with one to four substituents independently selected from F, Cl, OH, CN, methyl, ethyl, NH2, NHCH3, N(CH3)2 and methoxy,
• or alternatively, Het is a 6-membered ring containing one or 2 N atoms fused at the 3,4-positions, relative to the attachment to the pyrrolidine ring, to a 5-membered aromatic ring containing one or two further N atoms, which 5-membered ring is optionally substituted with OH,
• or a pharmaceutically acceptable salt thereof.